Evgen Pharma PLC Investor Presentation in Manchester
19 Novembre 2018 - 8:00AM
RNS Non-Regulatory
TIDMEVG
Evgen Pharma PLC
19 November 2018
For immediate release 19 November 2018
RNS REACH
Evgen Pharma plc
("Evgen" or "the Company")
Investor Presentation in Manchester
Evgen Pharma plc (AIM: EVG), a clinical stage drug development
company focused on the treatment of cancer and neurological
conditions, announces that Steve Franklin, the Company's CEO, will
be presenting tomorrow evening at a ShareSoc Growth Company Seminar
in Manchester.
In the presentation, Steve Franklin will outline the Company's
proprietary technology and describe its two on-going Phase II
trials in metastatic breast cancer and subarachnoid haemorrhage. He
will also answer any questions from investors.
The ShareSoc event, which is primarily for private investors,
starts at 5.30pm on 20 November 2018 and is being held at the
DoubleTree by Hilton Hotel, One Piccadilly Place, 1 Auburn Street,
Manchester M1 3DG.
Further details of the event, along with a registration form,
are available at this link:
https://www.sharesoc.org/events/sharesoc-growth-company-seminar-in-manchester-20-november-2018/
Enquiries:
Evgen Pharma plc c/o +44 (0) 20 7466 5000
Dr Stephen Franklin, CEO
Richard Moulson, CFO
www.evgen.com
Buchanan
Mark Court, Sophie Wills, Tilly Abraham +44 (0) 20 7466 5000
Northland Capital Partners Limited
Matthew Johnson, Gerry Beaney (Corporate
Finance)
Rob Rees (Corporate Broking) +44 (0) 20 3861 6625
WG Partners LLP
Nigel Barnes, Claes Spång +44 (0) 20 3705 9330
Notes for editors:
About Evgen Pharma plc
Evgen is a clinical stage drug development company whose lead
programmes are in breast cancer and subarachnoid haemorrhage, a
type of stroke. The Company's core technology is Sulforadex(R), a
method for synthesising and stabilising the naturally occurring
compound sulforaphane and novel proprietary analogues based on
sulforaphane. The lead product, SFX-01, is a patented composition
of synthetic sulforaphane and alpha-cyclodextrin.
Evgen commenced operations in January 2008 and has its
headquarters at The Colony, Wilmslow, Cheshire, and its registered
office at the Liverpool Science Park, Liverpool. It joined the AIM
market of the London Stock Exchange in October 2015 and trades
under the ticker symbol EVG.
For further information, please visit: www.evgen.com
For commissioned research on the Company, please visit:
http://evgen.com/investors/analyst-coverage/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAUNANRWNAAAAA
(END) Dow Jones Newswires
November 19, 2018 02:00 ET (07:00 GMT)
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Set 2024 a Ott 2024
Grafico Azioni Evgen Pharma (LSE:EVG)
Storico
Da Ott 2023 a Ott 2024